EURECA Finalizes Database Lock

EURECA aims to provide information on the epidemiology, risk factors, clinical management and attributable outcomes of key infections (pneumonia, intra-abdominal, urinary and bloodstream infections) due to carbapenem-resistant Enterobacterales (CRE) in order to inform the design of randomized trials and provide high-quality comparative historical cohorts. In addition, bloodstream infections due to carbapenem-resistant Acinetobacter baumannii (CRAB) were collected. The study was performed in 50 sites across 9 European countries.

More than 2000 patients were prospectively recruited, including 770 patients with infections due to CRE, 266 control patients with carbapenem-susceptible Enterobacterales, 817 control patients without infection, and 244 patients with bloodstream infections due to CRAB. The database contains comprehensive epidemiological, clinical and outcome data, which have been monitored for quality. Also, all the CRE and CRAB isolates were collected, which have already been confirmed in the central laboratories of the project, which are working on advanced microbiological characterization.

The EURECA team acknowledges the huge effort and commitment of all partners, national coordinators and local investigators to achieve this important study milestone. The excellent collaboration among the coordination team and the study sites has ensured a smooth run of the study.

EURECA is developed within WP1A and WP1B of COMBACTE-CARE. The project is led by the groups at Hospital Universitario Virgen Macarena (WP1A) and University of Antwerp (WP1B), with GlaxoSmithKline being the EFPIA co-lead. The partners include the University Medical Center Utrecht, University Hospitals of Geneva, the University of Ulm, the University Medical Center of Athens, National Institute of Public Health of Kosovo,  St. George University of London, University Hospital Ramón y Cajal, Cardiff University, University of Freiburg, ISGlobal, and Basilea Pharmaceuticals.